secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001104659-25-103254
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio raises ~$3.4M in offering of 1.67M shares at $2.05 for Alzheimer's trial
--------------------------------------------------------------------------------

- 1,670,732 shares at $2.05 each; gross proceeds ~$3.425M before expenses.
- Two board members purchase 1,073,171 shares under separate subscription agreements.
- Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.
- Placement agent H.C. Wainwright receives 7% cash fee and warrants for 83,537 shares at $2.5625.
- Closing expected October 28, 2025; lock-up on further issuance until November 28, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925103254/0001104659-25-103254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925103254/tm2529544d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-103254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer